142 related articles for article (PubMed ID: 24747810)
1. Characterization of protein-adjuvant coencapsulation in microparticles for vaccine delivery.
Mathew S; Lendlein A; Wischke C
Eur J Pharm Biopharm; 2014 Jul; 87(2):403-7. PubMed ID: 24747810
[TBL] [Abstract][Full Text] [Related]
2. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
3. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
4. Potential of NOD receptor ligands as immunomodulators in particulate vaccine carriers.
Wischke C; Mathew S; Roch T; Frentsch M; Lendlein A
J Control Release; 2012 Dec; 164(3):299-306. PubMed ID: 22771980
[TBL] [Abstract][Full Text] [Related]
5. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
6. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
[TBL] [Abstract][Full Text] [Related]
7. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.
Jain S; O'Hagan DT; Singh M
Expert Rev Vaccines; 2011 Dec; 10(12):1731-42. PubMed ID: 22085176
[TBL] [Abstract][Full Text] [Related]
8. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles.
Zhao A; Rodgers VG
J Control Release; 2006 Jun; 113(1):15-22. PubMed ID: 16707186
[TBL] [Abstract][Full Text] [Related]
9. Encapsulation of antigen in poly(D,L-lactide-co-glycolide) microspheres protects from harmful effects of γ-irradiation as assessed in mice.
Mohanan D; Gander B; Kündig TM; Johansen P
Eur J Pharm Biopharm; 2012 Feb; 80(2):274-81. PubMed ID: 22024408
[TBL] [Abstract][Full Text] [Related]
10. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles.
Martínez Gómez JM; Fischer S; Csaba N; Kündig TM; Merkle HP; Gander B; Johansen P
Pharm Res; 2007 Oct; 24(10):1927-35. PubMed ID: 17541735
[TBL] [Abstract][Full Text] [Related]
11. Protein-loaded poly(epsilon-caprolactone) microparticles. II. Muramyl dipeptide for oral controlled release of adjuvant.
Youan BB; Benoit MA; Rollmann B; Riveau G; Gillard J
J Microencapsul; 1999; 16(5):601-12. PubMed ID: 10499840
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid-PLGA hybrid nanoparticles.
Liu L; Ma P; Wang H; Zhang C; Sun H; Wang C; Song C; Leng X; Kong D; Ma G
J Control Release; 2016 Mar; 225():230-9. PubMed ID: 26826307
[TBL] [Abstract][Full Text] [Related]
13. Antigen delivery via hydrophilic PEG-b-PAGE-b-PLGA nanoparticles boosts vaccination induced T cell immunity.
Rietscher R; Schröder M; Janke J; Czaplewska J; Gottschaldt M; Scherließ R; Hanefeld A; Schubert US; Schneider M; Knolle PA; Lehr CM
Eur J Pharm Biopharm; 2016 May; 102():20-31. PubMed ID: 26940132
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant effect of microencapsulated NOD ligands studied in a human phagocytic cell line.
Mathew S; Roch T; Frentsch M; Lendlein A; Wischke C
J Appl Biomater Funct Mater; 2012; 10(3):229-36. PubMed ID: 23258559
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
Zhang XQ; Dahle CE; Weiner GJ; Salem AK
J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
[TBL] [Abstract][Full Text] [Related]
16. Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines.
Wang C; Muttil P; Lu D; Beltran-Torres AA; Garcia-Contreras L; Hickey AJ
AAPS J; 2009 Mar; 11(1):139-47. PubMed ID: 19277872
[TBL] [Abstract][Full Text] [Related]
17. Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles.
Du G; Hathout RM; Nasr M; Nejadnik MR; Tu J; Koning RI; Koster AJ; Slütter B; Kros A; Jiskoot W; Bouwstra JA; Mönkäre J
J Control Release; 2017 Nov; 266():109-118. PubMed ID: 28943194
[TBL] [Abstract][Full Text] [Related]
18. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency.
Kazzaz J; Singh M; Ugozzoli M; Chesko J; Soenawan E; O'Hagan DT
J Control Release; 2006 Feb; 110(3):566-73. PubMed ID: 16360956
[TBL] [Abstract][Full Text] [Related]
19. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy.
Joshi VB; Adamcakova-Dodd A; Jing X; Wongrakpanich A; Gibson-Corley KN; Thorne PS; Salem AK
AAPS J; 2014 Sep; 16(5):975-85. PubMed ID: 24981892
[TBL] [Abstract][Full Text] [Related]
20. In vivo investigation of twin-screw extruded lipid implants for vaccine delivery.
Even MP; Young K; Winter G; Hook S; Engert J
Eur J Pharm Biopharm; 2014 Jul; 87(2):338-46. PubMed ID: 24607791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
